Versucht aus den Beispielen menschlicher Übersetzungen das Übersetzen zu lernen.
Von professionellen Übersetzern, Unternehmen, Websites und kostenlos verfügbaren Übersetzungsdatenbanken.
treatment of emphysema secondary to congenital alpha- 1
treatment of emphysema secondary to congenital alpha- 1 antitrypsin deficiency
treatment of emphysema secondary to congenital alpha1 - antitrypsin deficieny
treatment of emphysema secondary to congenital alpha1- antitrypsin deficieny
treatment of emphysema secondary to congenital alpha- 1 - antitrypsin deficiency
treatment of emphysema secondary to congenital alpha- 1- antitrypsin deficiency
gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol.
gemfibrosiili alhaisen hd- lipoproteiinikolesterolitason omaavien miesten sepelvaltimotaudin sekundaariehkäisyssä.
position paper on the regulatory requirements for the authorisation of low- dose modified release asa formulations in the secondary prevention of cardiovascular events.
position paper on the regulatory requirements for the authorisation of low- dose modified release asa formulations in the secondary prevention of cardiovascular events.
the european school provides a multilingual , multicultural and multi-denominational education for nursery , primary and secondary-level pupils .
the european school provides a multilingual , multicultural and multi-denominational education for nursery , primary and secondary-level pupils .
på vegne af federal trust og secondary schools association of the european union vil jeg gerne takke dem, fru kommissær, og deres generaldirektorat for den uvurderlige støtte, som de har ydet til et projekt om borgerskab.
federal trustin ja euroopan unionin oppikoulujen ja lukioiden järjestön( the secondary schools association of the european union) puolesta haluaisin kiittää teitä, arvoisa komissaari, ja teidän pääosastoanne siitä korvaamattomasta tuesta, jota te olette antaneet kansalaishankkeelle.
mere specifikt knytter cbp et notat til passagerens sekundære kontrolregister (secondary examination record) for at angive, at visse pnr-oplysninger kan være eller er ukorrekte.
cbp varustaa matkustajan toisen tutkimustiedoston huomautuksilla joidenkin pnr-tiedostossa olevien tietojen mahdollisesta tai vahvistetusta virheellisyydestä.
arbejdsgiveren skal betale sekundñre gruppe 1bidrag (secondary class 1 contributions), hvis arbejdstagerens indtñgt overstiger den sekundñre grñnse Ð arbejdsgiverens bidrag fratrñkkes ikke arbejdstagerens lùn, men er arbejdsgiverens ansvar.
tyoÈnantaja maksaa toissijaiset 1. luokan vakuutusmaksut, jos vakuutetun ansiot ylittaÈvaÈt toissijaisen kynnyksen ± tyoÈnantajamaksuja ei vaÈhennetaÈ palkasta, vaan niistaÈ vastaa tyoÈnantaja .
titel på dokumentet note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti- depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti- bacterial medicinal product (cpmp/ ewp/ 558/ 95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
asiakirjan nimi note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti- depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti- bacterial medicinal product (cpmp/ ewp/ 558/ 95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: